trending Market Intelligence /marketintelligence/en/news-insights/trending/0A5YjRns1bOdaV4-fhV25Q2 content esgSubNav
In This List

Ovid Therapeutics drug gets FDA orphan drug status for rare epilepsy disorder

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Ovid Therapeutics drug gets FDA orphan drug status for rare epilepsy disorder

The U.S. Food and Drug Administration granted orphan drug designation to Ovid Therapeutics Inc.'s TAK-935/OV935 to treat Lennox-Gastaut syndrome, a rare form of epilepsy.

In January, Takeda Pharmaceutical Co. Ltd. and Ovid formed a global collaboration to develop and commercialize TAK-935/OV935 to treat developmental and epileptic encephalopathies, a group of rare epilepsies that cause morbidities and can worsen over time.

The agency previously granted orphan drug status to the drug for the treatment of Dravet syndrome, another rare form of epilepsy.